Chi Chen, Liu Yifan, Xu Yawei, Xu Dachun
Department of Cardiology, Shanghai Tenth People's Hospital, Tongji University School of Medicine, Shanghai, China.
Front Cardiovasc Med. 2021 Aug 11;8:707162. doi: 10.3389/fcvm.2021.707162. eCollection 2021.
Cardiovascular diseases are the leading cause of mortality in the world. Heart failure with preserved ejection fraction (HFpEF) accounts for about half of all heart failure. Unfortunately, the mechanisms of HFpEF are still unclear, leading to little progress of effective treatment of HFpEF. Arterial stiffness is the decrement of arterial compliance. The media of large arteries degenerate in both physiological and pathological conditions. Many studies have proven that arterial stiffness is an independent risk factor for cardiovascular disorders including diastolic dysfunction. In this perspective, we discussed if arterial stiffness is related to HFpEF, and how does arterial stiffness contribute to HFpEF. Finally, we briefly summarized current treatment strategies on arterial stiffness and HFpEF. Though some new drugs were developed, the safety and effectiveness were not adequately assessed. New pharmacologic treatment for arterial stiffness and HFpEF are urgently needed.
心血管疾病是全球主要的死亡原因。射血分数保留的心力衰竭(HFpEF)约占所有心力衰竭病例的一半。遗憾的是,HFpEF的发病机制仍不清楚,导致HFpEF的有效治疗进展甚微。动脉僵硬度是指动脉顺应性降低。在生理和病理条件下,大动脉的中膜都会发生退变。许多研究已证实,动脉僵硬度是包括舒张功能障碍在内的心血管疾病的独立危险因素。从这个角度出发,我们探讨了动脉僵硬度是否与HFpEF相关,以及动脉僵硬度如何导致HFpEF。最后,我们简要总结了目前针对动脉僵硬度和HFpEF的治疗策略。尽管研发了一些新药,但其安全性和有效性尚未得到充分评估。迫切需要针对动脉僵硬度和HFpEF的新型药物治疗。